Francois Cedric 4

What Happened

• Francois Cedric, CEO of Apellis Pharmaceuticals (APLS), was granted 195,952 restricted stock units (RSUs) on January 28, 2026. The Form 4 reports the acquisition as 195,952 shares at $0.00 (typical for RSU grants), total reported value $0 on the form.

Key Details

• Transaction date: 2026-01-28; filing date: 2026-01-30.
• Transaction type/code: Award/Grant (A) — Restricted Stock Units (RSUs).
• Grant size: 195,952 RSUs; price per share on form: $0.00.
• Vesting: 25% annually over four years from the grant date, subject to continued service (footnote F1).
• Shares owned after transaction: not specified in the filing.
• Trust/ownership notes: certain Apellis shares are held in several trusts (The Cedric Francois Irrevocable Trusts of 2023 and others). The reporting person disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest (footnotes F2–F5).
• No indication in the filing that this was a sale or exercise; it is a compensation award.

Context

• RSU grants are compensation and typically vest over time; they do not represent an immediate cash purchase or sale. Such awards are common for executive pay and do not by themselves indicate the executive’s near-term buying or selling intentions.